ZS Pharma Acquired, Nasdaq: ZSPH
Late-stage biotech developing a treatment for excess potassium (hyperkalemia).
Industry: Health Care
First Day Return: +57.7%
Industry: Health Care
ZSPH
Late-stage biotech developing a treatment for excess potassium (hyperkalemia).
| IPO Data | |
|---|---|
| IPO File Date | 05/15/2014 |
| Offer Price | $18.00 |
| Price Range n/a | |
| Offer Shares (mm) | 5.9 |
| Deal Size ($mm) | $107 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 06/17/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $107 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Coppell, TX, United States |
| Founded | 2008 |
| Employees at IPO | 41 |
| Website www.zspharma.com | |
IPO News for ZS Pharma
ZS Pharma (ZSPH) Performance
